VIA
ITOS

Vident Investment Advisory’s iTeos Therapeutics ITOS Stock Holding History

Vident Investment Advisory’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-32,887
Closed -$448K – 1263
2023
Q1 		$448K Sell
32,887
-1,134
-3% -$20.3K 0.01% 815
2022
Q4 		$664K Sell
34,021
-33
-0.1% -$645 0.03% 616
2022
Q3 		$649K Sell
34,054
-3,648
-10% -$84K 0.02% 707
2022
Q2 		$777K Buy
37,702
+8,719
+30% +$207K 0.02% 710
2022
Q1 		$933K Buy
28,983
+4,830
+20% +$176K 0.02% 712
2021
Q4 		$1.13M Buy
+24,153
New +$804K 0.03% 659

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vident Investment Advisory's ITOS Position: Q2 2023 in Review

Vident Investment Advisory sold out of iTeos Therapeutics (ITOS) in Q2 2023, closing a stake of 32,887 shares — an estimated $448K sold.

Vident Investment Advisory first reported a position in ITOS in Q4 2021 and held it in 6 quarters. The position peaked at $1.13M in Q4 2021. 146 funds tracked by Wall St. Rank hold ITOS as of Q2 2023.

  • Vident Investment Advisory reported no remaining iTeos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 32,887 iTeos Therapeutics shares in Q2 2023, an estimated $448K.
  • Vident Investment Advisory first reported a position in iTeos Therapeutics in Q4 2021 and held it in 6 quarters.
  • Vident Investment Advisory's iTeos Therapeutics position peaked at $1.13M in Q4 2021.
  • 146 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.